• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非常轻度至重度痴呆和死亡率:14 年随访 - 奥登塞研究。

Very mild to severe dementia and mortality: A 14-year follow-up - The Odense study.

机构信息

Department of Psychiatry, Odense University Hospital, Denmark.

出版信息

Dement Geriatr Cogn Disord. 2010;29(1):61-7. doi: 10.1159/000265553. Epub 2010 Jan 27.

DOI:10.1159/000265553
PMID:20110702
Abstract

BACKGROUND/AIMS: To examine the mortality of very mildly to severely demented persons compared to nondemented persons.

METHODS

Participants in a randomly drawn population-based cohort study on dementia were followed for 14 years from 1992 to 2006. Participants were examined at baseline (3,065 nondemented and 234 prevalent demented), after 2 years (2,286 nondemented and 145 incident demented) and again after 5 years (1,669 nondemented and 124 new cases of dementia). Causes of death were ascertained in 884 nondemented and 286 demented participants. Survival for demented compared to nondemented persons was analyzed with the Cox proportional hazards model with time-dependent covariates adjusted for gender and age.

RESULTS

The hazard ratio of death (95% confidence interval) increased from 1.82 (1.55-2.14) for the very mildly demented to 9.52 (6.60-13.74) for the severely demented subjects. The demented participants died significantly more often of neurological causes other than dementia and of pneumonia than the nondemented participants. No other significant differences in causes of death were found.

CONCLUSION

Dementia increased the risk of death. Even in the very early stages of dementia the risk of death was increased.

摘要

背景/目的:检查轻度至重度痴呆患者与非痴呆患者的死亡率。

方法

对一项基于人群的痴呆症随机抽样队列研究中的参与者进行了 14 年的随访,从 1992 年到 2006 年。在基线时(3065 名非痴呆患者和 234 名现患痴呆患者)、2 年后(2286 名非痴呆患者和 145 名新发痴呆患者)以及 5 年后(1669 名非痴呆患者和 124 名新发痴呆患者)对参与者进行了检查。在 884 名非痴呆患者和 286 名痴呆患者中确定了死因。使用 Cox 比例风险模型分析痴呆与非痴呆患者的生存情况,该模型调整了性别和年龄的时间依赖性协变量。

结果

死亡风险比(95%置信区间)从轻度痴呆患者的 1.82(1.55-2.14)增加到重度痴呆患者的 9.52(6.60-13.74)。痴呆患者死于非痴呆原因的神经系统疾病和肺炎的比例明显高于非痴呆患者。未发现其他死因的显著差异。

结论

痴呆症增加了死亡风险。即使在痴呆症的早期阶段,死亡风险也会增加。

相似文献

1
Very mild to severe dementia and mortality: A 14-year follow-up - The Odense study.非常轻度至重度痴呆和死亡率:14 年随访 - 奥登塞研究。
Dement Geriatr Cogn Disord. 2010;29(1):61-7. doi: 10.1159/000265553. Epub 2010 Jan 27.
2
Dementia-associated mortality at thirteen years in the NEDICES Cohort Study.十三年来 NEDICES 队列研究中与痴呆相关的死亡率。
J Alzheimers Dis. 2011;26(3):543-51. doi: 10.3233/JAD-2011-110443.
3
Incident dementia cases and mortality. Results of the leipzig Longitudinal Study of the Aged (LEILA75+).新发痴呆病例与死亡率。莱比锡老年纵向研究(LEILA75+)的结果。
Dement Geriatr Cogn Disord. 2006;22(3):185-93. doi: 10.1159/000094786. Epub 2006 Jul 28.
4
Mortality after a diagnosis of dementia in a population aged 75 and over in Spain.西班牙75岁及以上人群确诊痴呆症后的死亡率。
Neuroepidemiology. 2008;31(2):80-8. doi: 10.1159/000144088. Epub 2008 Jul 12.
5
Early-onset dementia is associated with higher mortality.早发性痴呆与较高的死亡率相关。
Dement Geriatr Cogn Disord. 2008;26(2):147-52. doi: 10.1159/000149585. Epub 2008 Aug 4.
6
Mortality in individuals with mild cognitive impairment. Results of the Leipzig Longitudinal Study of the Aged (LEILA75+).轻度认知障碍个体的死亡率。莱比锡老年纵向研究(LEILA75+)的结果。
Neuroepidemiology. 2007;29(3-4):226-34. doi: 10.1159/000112479. Epub 2007 Dec 13.
7
[MMSE for survival prognostics in dementia].[用于痴呆症生存预后评估的简易精神状态检查表]
Psychiatr Prax. 2010 Mar;37(2):78-83. doi: 10.1055/s-0029-1223473. Epub 2010 Feb 24.
8
Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people.利用磁共振成像测量海马体和杏仁核体积来预测认知功能正常老年人的痴呆症。
Arch Gen Psychiatry. 2006 Jan;63(1):57-62. doi: 10.1001/archpsyc.63.1.57.
9
APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study.载脂蛋白E基因型、痴呆家族史与阿尔茨海默病风险:一项6年随访研究
Arch Neurol. 2004 Dec;61(12):1930-4. doi: 10.1001/archneur.61.12.1930.
10
Serum surfactant protein D is correlated to development of dementia and augmented mortality.血清表面活性蛋白D与痴呆症的发展及死亡率增加相关。
Clin Immunol. 2007 Jun;123(3):333-7. doi: 10.1016/j.clim.2007.03.001. Epub 2007 Apr 20.

引用本文的文献

1
Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer's Disease: A U.S. Cost Comparison Model.皮下注射与静脉注射lecanemab治疗早期阿尔茨海默病的社会成本与效率:美国成本比较模型
Neurol Ther. 2025 Jul 4. doi: 10.1007/s40120-025-00790-2.
2
Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer's disease.阿杜卡单抗与安慰剂治疗轻度认知障碍和轻度阿尔茨海默病患者的成本效益分析。
BMJ Open. 2025 Apr 17;15(4):e090403. doi: 10.1136/bmjopen-2024-090403.
3
Hospital admissions for dementia in the Brazilian public health system over the last decade.
过去十年巴西公共卫生系统中因痴呆症而住院的情况。
Alzheimers Dement (Amst). 2024 Oct 10;16(4):e70017. doi: 10.1002/dad2.70017. eCollection 2024 Oct-Dec.
4
Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment.优化阿尔茨海默病的诊断与治疗:评估在临床实践中整合血液生物标志物用于疾病修饰治疗的成本效益。
J Prev Alzheimers Dis. 2024;11(4):928-942. doi: 10.14283/jpad.2024.67.
5
Cholinesterase inhibitors and memantine are associated with a reduced mortality in nursing home residents with dementia: a longitudinal observational study.胆碱酯酶抑制剂和美金刚与养老院痴呆患者的死亡率降低相关:一项纵向观察研究。
Alzheimers Res Ther. 2024 May 29;16(1):117. doi: 10.1186/s13195-024-01481-0.
6
Disease severity and mortality in Alzheimer's disease: an analysis using the U.S. National Alzheimer's Coordinating Center Uniform Data Set.阿尔茨海默病的疾病严重程度和死亡率:使用美国国家阿尔茨海默病协调中心统一数据集进行的分析。
BMC Neurol. 2023 Aug 14;23(1):302. doi: 10.1186/s12883-023-03353-w.
7
Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.预测日本早期阿尔茨海默病中lecanemab的社会价值:一项患者层面的模拟研究
Neurol Ther. 2023 Aug;12(4):1133-1157. doi: 10.1007/s40120-023-00492-7. Epub 2023 May 15.
8
A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.改善阿尔茨海默病护理的途径:从CLARITY AD试验模拟lecanemab在早期阿尔茨海默病中的长期健康结局
Neurol Ther. 2023 Jun;12(3):863-881. doi: 10.1007/s40120-023-00473-w. Epub 2023 Apr 2.
9
Effect of mortality in cost-effectiveness modeling of disease-modifying treatment for Alzheimer's disease.死亡率在阿尔茨海默病疾病修饰治疗成本效益模型中的影响。
Alzheimers Dement (Amst). 2023 Mar 29;15(1):e12422. doi: 10.1002/dad2.12422. eCollection 2023 Jan-Mar.
10
Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.使用模拟模型评估早期阿尔茨海默病患者中lecanemab的社会价值。
Neurol Ther. 2023 Jun;12(3):795-814. doi: 10.1007/s40120-023-00460-1. Epub 2023 Mar 16.